113 related articles for article (PubMed ID: 8731322)
1. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
Fonseca FA; Novazzi JP; Cendoroglo MS; Duarte M; Almeida Pinto LE; Rabelo LM; da Rocha Martinez TL
Arq Bras Cardiol; 1996 Jan; 66(1):33-5. PubMed ID: 8731322
[TBL] [Abstract][Full Text] [Related]
2. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
Krüger B
Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
[TBL] [Abstract][Full Text] [Related]
3. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
[TBL] [Abstract][Full Text] [Related]
5. Etofibrate treatment alters low density lipoprotein susceptibility to lipid peroxidation.
Wülfroth P; Richter CM; Burkard M; Huth K; Quack G
Drugs Exp Clin Res; 1992; 18(11-12):469-74. PubMed ID: 1308472
[TBL] [Abstract][Full Text] [Related]
6. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Freyberger H; Schifferdecker E; Schatz H
Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
[TBL] [Abstract][Full Text] [Related]
7. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Espinosa RA; Rodríguez-Roa E; Nagy E; Mijares ME; Rodríguez-Larralde A; Gil A; Lundberg U; Carvajal Z; Castillo L; Arocha-Piñango CL
Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
[TBL] [Abstract][Full Text] [Related]
8. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
Waysbort J; Schwartz S; Brunner D
Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
[TBL] [Abstract][Full Text] [Related]
10. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
[TBL] [Abstract][Full Text] [Related]
11. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
Virgolini I; Koller E; Li S; Yang Q; Banyai M; Rauscha F; Pidlich J; Pirker W; Sinzinger H
Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
[TBL] [Abstract][Full Text] [Related]
12. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
13. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Kovács I; Tarján J; Császár A
Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
[TBL] [Abstract][Full Text] [Related]
15. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
16. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
17. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
Simpson IA; Lorimer AR; Walker ID; Davidson JF
Thromb Haemost; 1985 Aug; 54(2):442-4. PubMed ID: 4082082
[TBL] [Abstract][Full Text] [Related]
18. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Fincham JE; Quack G; Wülfroth P; Benadé AJ
Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
[TBL] [Abstract][Full Text] [Related]
19. Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?
Sener A; Ozsavci D; Oba R; Demirel GY; Uras F; Yardimci KT
Clin Biochem; 2005 Dec; 38(12):1081-7. PubMed ID: 16253220
[TBL] [Abstract][Full Text] [Related]
20. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]